Ignite Creation Date:
2025-12-24 @ 2:48 PM
Ignite Modification Date:
2025-12-25 @ 11:51 PM
Study NCT ID:
NCT04476459
Status:
UNKNOWN
Last Update Posted:
2021-03-15
First Post:
2020-07-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL
Sponsor:
Huiqiang Huang
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
CARD
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None